# Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC

> **NCT03326674** · PHASE3 · TERMINATED · sponsor: **Odonate Therapeutics, Inc.** · enrollment: 685 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Tesetaxel and Capecitabine
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT03326674
- **Lead sponsor:** Odonate Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-21
- **Primary completion:** 2020-08-24
- **Final completion:** 2021-06-28
- **Target enrollment:** 685 (ACTUAL)
- **Why stopped:** The Sponsor has discontinued the development of tesetaxel
- **Last updated:** 2021-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03326674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03326674, "Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03326674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*